Screener
Theravance Biopharma TBPH EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from Theravance Biopharma’s reported figures.
Based on trailing twelve months.
The source filing: Theravance Biopharma’s 10-Q, filed August 11, 2026. Open the filing →
- Filed
- Aug 11, 2026, 8:00 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-093773
FAQ
- What is Theravance Biopharma's EBITDA margin?
- Theravance Biopharma (TBPH) reported EBITDA margin of -2.5% in Q2 2026.
- How has Theravance Biopharma's EBITDA margin changed year-over-year?
- Theravance Biopharma's EBITDA margin increased by 94.5% year-over-year, from -46% to -2.5%.
- What is the long-term trend for Theravance Biopharma's EBITDA margin?
- Over 4 years (2021 to 2025), Theravance Biopharma's EBITDA margin has grown at a -74.8% compound annual growth rate (CAGR), from -457.4% to -1.8%.
- What does EBITDA margin mean?
- EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.
Ask your AI about Theravance Biopharma's ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude